CMMB Q3 2022 Earnings — Chemomab Therapeutics Ltd. Revenue & Financial Results | Market Cap Arena

CMMBChemomab Therapeutics Ltd.

$12M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$8M

Operating Income

-$8M

Net Income

-$8M

EPS (Diluted)

$-2.78

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$50M

Total Liabilities

$6M

Stockholders' Equity

$45M

Cash & Equivalents

$11M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$8M	-$9,042	-91881.9%
Operating Income	-$8M	-$3M	-187.7%
Net Income	-$8M	-$3M	-180.2%